drugset
drugset / Trial / NCT07273396

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

NCT07273396 ↗

Phase 1/2 Not yet recruiting 53 enrolled Seoul National University Hospital
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.

Timeline

Start
2026-01-01
Primary completion
2030-04-30
Completion
2030-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 10 mg/m2 Other
Subject Paclitaxel Small molecule 20 mg/m2 Other
Subject Paclitaxel Small molecule 40 mg/m2 Other
Subject Paclitaxel Small molecule 67 mg/m2 Other
Subject Paclitaxel Small molecule 100 mg/m2 Other
Subject Paclitaxel Small molecule 140 mg/m2 Other

Indications

ovarian neoplasm peritoneal neoplasm